Pages
Products
Human EGFR-Del19/T790M/L858R Stable Cell Line-Ba/F3

Human EGFR-Del19/T790M/L858R Stable Cell Line-Ba/F3

Cat.No. :  CSC-RO0239 Host Cell:  Ba/F3

Size:  >1x10^6 frozen cells/vial, 1 mL Stability:  Stable in culture over a minimum of 10 passages

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Informationn

Cat. No. CSC-RO0239
Description This cell line stably expresses human EGFR gene bearing exon19 E746_A750 deletion, L858R and T790M triple mutations
Target Gene EGFR
Gene Species Homo sapiens (Human)
Host Cell Ba/F3
Host Cell Species Mus musculus (Mouse)
Stability Stable in culture over a minimum of 10 passages
Application Drug screening and biological assays
Growth Conditions 37 °C, 5% CO2
Quality Control Negative for bacteria, yeast, fungi and mycoplasma.
Shipping Dry ice
Storage Liquid nitrogen
Size >1x10^6 frozen cells/vial, 1 mL
Biosafety Level 2
Thawing & Subculturing Instructions 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap.

2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely.

3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min.

4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker).

5. Incubate the culture at 37°C with 5% CO2.

6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL.
Growth Properties Suspension, round
Freeze Medium Frozen with 70% medium, 20% FBS, 10% DMSO
Freezing Instructions Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker).

1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use.

2. Keep the freezing medium on ice and label cryovials.

3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.

4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium.

5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium.

6. Aliquot 1 ml of the cell suspension into each cryovial.

7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.

8. Transfer vials to liquid nitrogen for long-term storage.
Gene Name
Gene Symbol
Synonyms
Gene Description
Gene ID
UniProt ID
mRNA Refseq
Protein Refseq
Chromosome Location
Function
Pathway
MIM
Mycoplasma Negative
Format One frozen vial containing millions of cells
Storage Liquid nitrogen
Safety Considerations

The following safety precautions should be observed.

1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum.

2. No eating, drinking or smoking while handling the stable line.

3. Wash hands after handling the stable line and before leaving the lab.

4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells.

5. All waste should be considered hazardous.

6. Dispose of all liquid waste after each experiment and treat with bleach.

Ship Dry ice
Quick Inquiry

Background

Case Study

Applications

Publications

Q & A

Customer Reviews

Exon19 E746_A750 deletion, L858R, and T790M triple mutations are present in the mutant version of the epidermal growth factor receptor (EGFR) expressed by the human EGFR-Del19/T790M/L858R stable cell line Ba/F3. Situated on chromosome 7p12.1, the EGFR gene produces a transmembrane glycoprotein that is a member of the protein kinase superfamily and acts as a receptor for the epidermal growth factor family. This receptor causes tyrosine autophosphorylation and receptor dimerization when it binds to its ligand, which in turn promotes cell division. Lung cancer is commonly linked to EGFR mutations, which are particularly important for the pathophysiology of non-small cell lung cancer (NSCLC). Ba/F3 is a murine pro-B cell line commonly used in signal transduction studies and drug screening assays. These cells are a perfect model for examining drug sensitivity and oncogenic signaling pathways since they are dependent on interleukin-3 (IL-3) for survival and growth. Ba/F3 cells can be grown under normal cell culture conditions with IL-3 added as a supplement. Clinical therapy of patients with non-small cell lung cancer (NSCLC) is complicated by the EGFR-Del19/T790M/L858R mutation, which imparts resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib. The development of innovative treatment approaches, including as combination therapy and second- and third-generation EGFR TKIs, that target EGFR mutations has been the main focus of research efforts. Effective targeted therapy for NSCLC patients with EGFR mutations will need an understanding of the molecular processes behind EGFR-mediated signaling pathways and drug resistance.

EGFR gene mutations like T790M and L858R cause osimertinib resistance in non-small cell lung cancer (NSCLC). These alterations complicate therapy, making resistance-overcoming techniques essential. The researchers explored the effectiveness of brigatinib against osimertinib-resistant EGFR mutants, including EGFR-T790M and C797S, through crystal structure analysis and mutagenesis assays. They identified novel mutations, such as L718M and G796S, which are resistant to all clinically available EGFR-TKIs. Additionally, the study demonstrated that BI-4020, a fourth-generation EGFR inhibitor, can overcome these resistance mutations but still faces challenges with minor mutations like L747P.

Figure 1 describes the IC50 values for brigatinib-resistant triple and quadruple EGFR mutant cells treated with various drugs, including gefitinib, afatinib, BI-4020, and panitumumab, and includes Western blot analysis of the treated cells to assess the effects on protein expression. (doi: 10.1038/s41698-024-00542-9)Figure 1. The researchers used ENU mutagenesis screening to identify resistance mutations in Ba/F3 cells expressing EGFR mutations, such as L718 and G796N, after treatment with brigatinib. (Suzuki M, et al., 2024)

Creative Biogene's Human EGFR-Del19/T790M/L858R Stable Cell Line-Ba/F3 is useful for NSCLC EGFR mutation-driven resistance studies. This cell line, intended to express prevalent NSCLC EGFR mutations, may be used to test new EGFR inhibitors and combination therapy against drug-resistant EGFR mutations.

1. Lung cancer treatment research: Using the human EGFR-Del19/T790M/L858R stable cell line Ba/F3, we simulated the complex EGFR mutations in non-small cell lung cancer (NSCLC), studied its resistance mechanism to existing treatment options, and explored new treatment strategies. 2. Drug resistance mechanism research: By analyzing the effects of EGFR triple mutations on cell proliferation and signal transduction, we revealed the role of these mutations in causing resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib, and promoted resistance-related research. 3. Drug screening and evaluation: Using the Ba/F3 cell model for drug screening, we evaluated the effectiveness of second- and third-generation EGFR TKIs and their combination therapies, and provided experimental support for the development of anti-tumor drugs. 4. Tumor signal transduction research: In-depth study of the role of EGFR triple mutations in the cell signal transduction network, revealing its specific mechanism in tumor occurrence and development, and providing a theoretical basis for targeted therapy. 5. Development of individualized treatment strategies: Based on the study of EGFR mutant cell lines, design individualized treatment plans to improve the clinical treatment effects of NSCLC patients and promote the development of precision medicine.
Customer Q&As
How pure is this human EGFR-Del19/T790M/L858R stable cell line? Is there any possibility of hybridization or mutation?

A: Our human EGFR-Del19/T790M/L858R stable cell line has undergone rigorous purification and verification procedures to ensure its purity and stability. We use a variety of techniques to identify cell lines, including PCR, immunofluorescence staining, and Western blot. We also regularly perform cytological testing of cell lines to ensure they are free of hybridization or mutation.

When studying the impact of EGFR-Del19/T790M/L858R multiple mutations on resistance to targeted therapy, what is the expression level of this stable cell line? Is relevant experimental data support provided?

A: Our human EGFR-Del19/T790M/L858R stable cell line has stable expression levels and has been widely used in anti-cancer drug resistance research. We provide detailed experimental data support that customers can refer to to evaluate the performance of our products.

Is this human EGFR-Del19/T790M/L858R stable cell line suitable for anti-cancer drug screening experiments? Is there relevant literature support?

A: Our human EGFR-Del19/T790M/L858R stable cell line has been widely used in anti-cancer drug screening experiments. We provide relevant literature support demonstrating the potential application of our products in anticancer drug screening.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Professional support

I recently used the Human EGFR-T790M Stable Cell Line-Ba/F3 for experiments, and the overall experience was excellent. This cell line stably expresses the T790M mutation of the human epidermal growth factor receptor (EGFR) and provides an important tool for studying EGFR-TKI resistance.

French

03/18/2021

Efficient research model

Human EGFR-T790M Stable Cell Line-Ba/F3 is a very efficient research model, especially suitable for studying the mechanism of EGFR-TKI resistance. This cell line stably expresses the T790M mutation of EGFR, simulating a common clinical resistance mechanism. Using this cell line for experiments, I obtained stable and reliable results. The service provided by the merchant was also very timely and professional, and they gave me full support and guidance.

United Kingdom

05/03/2022

Efficient service

The stability and consistency of the cell lines makes my research run more smoothly. The service quality provided by the boss is also very high. They responded quickly and provided professional technical support, which greatly improved my experimental efficiency.

United Kingdom

06/22/2022

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER